Literature DB >> 10972581

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group.

S E Manley1, I M Stratton, C A Cull, V Frighi, E A Eeley, D R Matthews, R R Holman, R C Turner, H A Neil.   

Abstract

AIMS: To assess the effect of diet on fasting plasma lipids and lipoproteins in patients with newly diagnosed Type 2 diabetes.
METHODS: A total of 2,906 patients each underwent 3 months' diet therapy before allocation to therapy in a randomized controlled clinical trial. Lipids and lipoproteins were measured at diagnosis and after 3 months' diet.
RESULTS: The mean body weight at diagnosis was 83 kg. Weight decreased after diet by a mean of 4.5 kg; body mass index (BMI) decreased by 1.51 kg/m2; plasma glucose fell by 3 mmol/l from 11 mmol/l; and HbA1c by 2% from 9%. Triglyceride concentrations were reduced in men by -0.41 (95% confidence interval (CI) -0.47 to - 0.35) mmol/l from a geometric mean 1.8 (1 SD interval 1.0-3.0) mmol/l, and in women by -0.23 (-0.28 to -0.18) mmol/l from a similar level. Cholesterol decreased in men by -0.28 (-0.33 to -0.24) mmol/l from 5.5 (1.1) mmol/l, and in women by -0.09 (-0.14 to -0.04) mmol/l from 5.8 (1.2) mmol/l with corresponding changes in LDL cholesterol. HDL cholesterol increased in men by 0.02 (0.01 to 0.04) mmol/l and in women by 0.01 (0 to 0.02) mmol/l. Triglyceride concentration in the top tertile was reduced by 37% in men (> 2.1 mmol/l) and by 23% in women (> 2.2 mmol/l) with regression to mean accounting for 13% and 6%, respectively. Similarly cholesterol in the top tertile was reduced by 12% in men (> 5.8 mmol/l) and 7% in women (> 6.2 mmol/l) with 6% of the decrease in both men and women accounted for by regression to the mean.
CONCLUSIONS: Initial dietary therapy in patients with newly diagnosed Type 2 diabetes substantially reduced plasma triglyceride, marginally improved total cholesterol and subfractions, and resulted in a potentially less atherogenic profile, although this did not eliminate the excess cardiovascular risk in patients with Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972581     DOI: 10.1046/j.1464-5491.2000.00320.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  16 in total

1.  Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes.

Authors:  Leonor Corsino; Mary Elizabeth Cox; Jennifer Rowel; Jennifer B Green
Journal:  Clin Med Ther       Date:  2009-08-27

Review 2.  [Pharmacotherapy of obesity].

Authors:  A Hamann
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

Review 3.  Review of electronic decision-support tools for diabetes care: a viable option for low- and middle-income countries?

Authors:  Mohammed K Ali; Seema Shah; Nikhil Tandon
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

4.  Incidence of diabetes after a partner's diagnosis.

Authors:  Solveig A Cunningham; Sara R Adams; Julie A Schmittdiel; Mohammed K Ali
Journal:  Prev Med       Date:  2017-08-18       Impact factor: 4.018

5.  Cardiovascular disease in type 2 diabetes: Attributable risk due to modifiable risk factors.

Authors:  John Zeber; Michael L Parchman
Journal:  Can Fam Physician       Date:  2010-08       Impact factor: 3.275

Review 6.  [Oral diabetes treatment. Which substance is indicated at which time?].

Authors:  A Hamann; M Morcos; P Nawroth
Journal:  Internist (Berl)       Date:  2004-12       Impact factor: 0.743

Review 7.  The effect of dietary intervention on serum lipid levels in type 2 diabetes mellitus.

Authors:  Nilo B Cater; Abhimanyu Garg
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

8.  Fat intake in patients newly diagnosed with type 2 diabetes: a 4-year follow-up study in general practice.

Authors:  Floris A van de Laar; Eloy H van de Lisdonk; Peter L B J Lucassen; J M H Tigchelaar; Saskia Meyboom; Jan Mulder; Henk J M van den Hoogen; Guy E H M Rutten; Chris van Weel
Journal:  Br J Gen Pract       Date:  2004-03       Impact factor: 5.386

9.  The role of PPAR-alpha agonists in the prevention of CVD in diabetes.

Authors:  Marja-Riitta Taskinen
Journal:  Curr Diab Rep       Date:  2007-04       Impact factor: 5.430

10.  Do improvements in dietary behaviour contribute to cardiovascular risk factor reduction over and above cardio-protective medication in newly diagnosed diabetes patients?

Authors:  A J M Cooper; D Schliemann; G H Long; S J Griffin; R K Simmons
Journal:  Eur J Clin Nutr       Date:  2014-05-07       Impact factor: 4.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.